Table 1 Selected studies evaluating angiogenesis inhibitors in advanced colorectal cancer

From: Treatment in advanced colorectal cancer: what, when and how?

Study

Treatment arms

Number of patients

Response rates (%)

P -value

Median progression-free survival (months)

P -value

Median overall survival (months)

P -value

First line

Kabbinavar et al (2003)

5-FU/LV

36

17

—

5.2

—

13.8

NR

 

5-FU/LV/BEV (5 mgkg−1)

35

40

0.029

9.0

0.005

21.5

NR

 

5-FU/LV/BEV (10 mgkg−1)

33

24

0.434

7.2

0.217

16.1

NR

Hurwitz et al (2004)

IFL

411

34.8

—

6.2

—

15.6

—

AVF 2107

IFL/BEV

402

44.8

0.004

10.6

<0.001

20.3

<0.001

 

5-FU/LV/BEV

110

40.0

0.66

8.8

0.4192

18.3

0.2521

Kabbinavar et al (2005b)

5-FU/LV

105

15.2

—

5.5

—

12.9

—

 

5-FU/LV/BEV

104

26.0

0.055

9.2

0.0002

16.6

0.16

Kabbinavar et al (2005a)

5-FU/LV or IFL

241

24.5

—

5.55

-

14.6

—

 

5-FU/LV/BEV

249

34.1

0.019

8.77

0.0001

17.9

0.0081

Saltz et al (2008)

FOLFOX or CAPOX

701

38

—

8.0

0.0023

19.9

0.077

XELOX-1/ NO16966

FOLFOX/CAPOX + BEV

699

38

0.99

9.4

 

21.3

 

Tol et al (2009)

CAPOX + BEV

368

50

—

10.7

—

20.3

—

CAIRO 2

CAPOX + BEV + cetuximab

368

52.7

0.49

9.4

0.01

19.4

0.16

Hecht et al (2009)

FOLFOX + BEV

410

48

—

11.4

HR: 1.27

24.5

HR: 1.43

PACCE

FOLFOX + BEV + PAN

413

46

NS

10.0

(95% CI: 1.06–1.52)

19.4

(95% CI: 1.11–1.83)

Hecht et al (2009)

FOLFIRI + BEV

115

40

—

11.7

HR: 1.19

20.5

HR: 1.42

PACCE

FOLFIRI + BEV + PAN

115

43

NS

10.1

(95% CI: 0.79–1.79

20.7

(95% CI: 0.77–2.62)

Reinacher-Schick et al (2008) a

CAPOX + BEV

127

53

—

10.4

—

26.7

—

AIO 0604

CAPIRI + BEV

120

55

NR

12.1

0.27

Not reached

0.55

Hecht et al (2009)

FOLFOX

583

46

—

7.7

—

20.5

—

CONFIRM 1

FOLFOX + PTK/ZK

585

42

NS

9.1

0.108

21.4

0.260

Grothey et al (2008b) BriTEb

Chemotherapy + BEV (non-randomised US cohort study)

1953

NR

NR

9.9

NR

25.1

NR

Berry et al (2008) (BEATb)

Chemotherapy + BEV (non-randomised non-US cohort study)

1914

NR

NR

10.8

NR

22.7

NR

Second line

Giantonio et al (2007)

FOLFOX

291

8.6

—

4.7

—

10.8

—

ECOG E3200

FOLFOX/BEV (10 mg kg−1)

289

22.7

<0.0001

7.3

<0.0001

12.9

0.0011

 

BEV (10 mg kg−1)

243

3.3

 

2.7

 

10.2

 

Kohne et al (2007)

FOLFOX

429

18

—

4.1

—

11.8

—

CONFIRM 2

FOLFOX + PTK/ZK

426

19

NS

5.6

0.026

12.1

0.511

Cunningham et al (2008) a

A. FOLFOX+BEV

66

27

 

7.8

B vs A

NR

—

HORIZON I

B. FOLFOX+cediranib (low dose)

71

18

—

5.8

0.29

NR

 
 

C. FOLFOX+cediranib (high dose)

73

19

NR

7.2

C vs A 0.79

NR

NS

Saltz et al (2007) a

Irinotecan/cetuximab/ BEV

43

37

—

7.3

—

14.5

—

BOND 2

Cetuximab/ BEV

40

20

NR

4.9

NR

11.4

NR

  1. LV=leucovorin; FOLFOX: oxaliplatin/infused 5-FU/LV; BEV=bevacizumab; CAPOX: capecitabine/oxaliplatin; IFL=irinotecan/bolus 5-FU/LV; FOLFIRI: irinotecan-infused 5-FU/LV; CAPIRI: capecitabine/irinotecan; PAN=panitumumab; NR=not reported; NS=Not significant; HR=hazard ratio; CI=confidence interval.
  2. The first treatment arm of each study was the control arm. Unless stated, all bevacixumab was given at 2.5 mg kg−1 per week. All P-values were compared with control arms.
  3. aRandomised phase II studies.
  4. bObservational registry studies.
Back to article page